User profiles for Gail V Matthews
 | Gail MatthewsKirby Institute, University of New South Wales Verified email at kirby.unsw.edu.au Cited by 13268 |
[HTML][HTML] Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection
A proportion of patients surviving acute coronavirus disease 2019 (COVID-19) infection develop
post-acute COVID syndrome (long COVID (LC)) lasting longer than 12 weeks. Here, we …
post-acute COVID syndrome (long COVID (LC)) lasting longer than 12 weeks. Here, we …
Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men
…, ML Chaix, M Fisher, H Gőtz, GV Matthews… - Gastroenterology, 2009 - Elsevier
BACKGROUND & AIMS: Since 2000, there has been a marked rise in acute hepatitis C
virus (HCV) in human immunodeficiency virus (HIV)-positive men who have sex with men (MSM). …
virus (HCV) in human immunodeficiency virus (HIV)-positive men who have sex with men (MSM). …
Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy
GV Matthews, A Bartholomeusz, S Locarnini, A Ayres… - Aids, 2006 - journals.lww.com
Background: Little is known about the prevalence and pattern of hepatitis B virus (HBV)
mutations in HIV/HBV co-infected individuals on long-term lamivudine (3TC) therapy. Methods: …
mutations in HIV/HBV co-infected individuals on long-term lamivudine (3TC) therapy. Methods: …
Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non …
…, J Lalezari, J Mallolas, M Bloch, GV Matthews… - The lancet HIV, 2015 - thelancet.com
Background Hepatitis C virus (HCV) infection is a leading cause of morbidity and mortality
in patients with HIV-1. The C-EDGE CO-INFECTION study assessed the efficacy, safety, and …
in patients with HIV-1. The C-EDGE CO-INFECTION study assessed the efficacy, safety, and …
[PDF][PDF] A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand
Coinfection with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) is
associated with considerable liver disease morbidity and mortality. Emerging HIV epidemics in …
associated with considerable liver disease morbidity and mortality. Emerging HIV epidemics in …
Changes in acquired immunodeficiency syndrome–related lymphoma since the introduction of highly active antiretroviral therapy
GV Matthews, M Bower, S Mandalia… - Blood, The Journal …, 2000 - ashpublications.org
Clinical data on 7840 HIV-positive patients, representing 43 745 patient-years of follow-up,
has been collected. All patients with ARL since 1986 (n = 150) were assessed at …
has been collected. All patients with ARL since 1986 (n = 150) were assessed at …
Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection
TJ Van De Laar, GV Matthews, M Prins, M Danta - Aids, 2010 - journals.lww.com
Since 2000 outbreaks of acute hepatitis C virus (HCV) among HIV-positive men who have
sex with men (MSM) who denied injecting drug use have been reported from Europe, the …
sex with men (MSM) who denied injecting drug use have been reported from Europe, the …
Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial
…, M Lacalamita, A Dunlop, GV Matthews… - The lancet …, 2018 - thelancet.com
Background Despite revised guidelines that no longer exclude people who inject drugs (PWID)
from treatment for hepatitis C virus (HCV) infection, many clinicians are reluctant to treat …
from treatment for hepatitis C virus (HCV) infection, many clinicians are reluctant to treat …
Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study
Background Guidelines recommend both protease inhibitor (PI)-and non-nucleoside
reverse transcriptase inhibitor (NNRTI)-containing regimens for initial therapy in HIV-positive …
reverse transcriptase inhibitor (NNRTI)-containing regimens for initial therapy in HIV-positive …
[PDF][PDF] Potential role for Interleukin‐28B genotype in treatment decision‐making in recent hepatitis C virus infection
…, K Petoumenos, M Hellard, GV Matthews… - …, 2010 - Wiley Online Library
Polymorphisms in the IL28B (interleukin‐28B) gene region are important in predicting outcome
following therapy for chronic hepatitis C virus (HCV) infection. We evaluated the role of …
following therapy for chronic hepatitis C virus (HCV) infection. We evaluated the role of …
